Welcome to our dedicated page for PRECISION BIOSCIENCES SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PRECISION BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PRECISION BIOSCIENCES's regulatory disclosures and financial reporting.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14–$4.15. Following the transaction, Brown’s direct beneficial ownership increased to 20,565 shares.
No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.
Precision BioSciences (NASDAQ: DTIL) filed a Form 4 disclosing that director Kevin Buehler purchased 5,076 shares of common stock on 25 Jun 2025 at a weighted-average price of $4.16 per share (trade range: $4.16–$4.18). After the transaction, Buehler directly owns 28,137 shares, an increase of roughly 22% in his personal stake. The transaction was coded “P” for an open-market purchase, and the filing reports no sales or derivative security activity. No Rule 10b5-1 trading plan was indicated.